Taiwan study checks safety of common lupus kidney drug
NCT ID NCT04645589
First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 30 times
Summary
This study followed 72 adults in Taiwan with lupus nephritis who were taking Myfortic (mycophenolate sodium) for the first time. Over 12 months, researchers tracked side effects, serious events, and reasons for stopping the drug. The goal was to understand how safe this treatment is in real-world use.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUPUS NEPHRITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Novartis Investigative Site
Kaohsiung City, 83301, Taiwan
-
Novartis Investigative Site
Keelung, 20401, Taiwan
-
Novartis Investigative Site
Taichung, 407219, Taiwan
-
Novartis Investigative Site
Taipei, 10002, Taiwan
-
Novartis Investigative Site
Taipei, 105, Taiwan
-
Novartis Investigative Site
Taoyuan, 33305, Taiwan
Conditions
Explore the condition pages connected to this study.